 BASKING RIDGE, N.J., Nov. 10, 2020 GLOBE NEWSWIRE -- Caladrius Biosciences, Inc. Nasdaq: CLBS Caladrius or the Company, a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces its presentation at American Heart Associations AHA Scientific Sessions, being held virtually November 13-17, 2020. 